CA4

Carbonic anhydrase 4 · P22748 · CA4 on Sugi Atlas →

342,422 patent compounds predicted against CA4, 207,284 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Pentetic Acid (SCHEMBL17138)	0.42	12/20
Acetazolamide (SCHEMBL23219)	1.00	9/20
SCHEMBL19687	0.70	8/20
Edetic Acid (SCHEMBL906)	0.42	8/20
Benzthiazide (SCHEMBL26257)	0.42	8/20
Coumarin (SCHEMBL6252)	1.00	7/20
SCHEMBL19880	0.55	7/20
SCHEMBL8588	0.43	7/20
Bicarbonate (SCHEMBL18628)	0.55	6/20
Glycolic Acid (SCHEMBL26512)	0.50	6/20
Edetic Acid (SCHEMBL24036)	0.45	6/20
Foscarnet (SCHEMBL7636)	0.44	6/20
SCHEMBL16810	0.42	6/20
Benzthiazide (SCHEMBL26258)	0.42	6/20
Edetic Acid (SCHEMBL5729)	0.37	6/20
Citric Acid (SCHEMBL3657)	1.00	5/20
Tiliroside (SCHEMBL23597)	1.00	5/20
Tiliroside (SCHEMBL23598)	1.00	5/20
Ketorolac (SCHEMBL4103)	0.59	5/20
Ketorolac (SCHEMBL14891)	0.59	5/20

Clinical trials — most relevant to CA4 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Zirconium-89-girentuximab PET/CT Imaging in Renal Cell Carcinoma	PHASE2/PHASE3	COMPLETED
A Study of the Safety and Efficacy of rhGAA in Patients With Infantile-onset Pompe Disease	PHASE2/PHASE3	COMPLETED
Study of [F 18]HX4 Positron Emission Tomography (PET) as a Tool to Detect Hypoxia in Tumors	PHASE2	COMPLETED
AB-2100, an Integrated Circuit T Cell Therapy in Patients With Recurrent Clear-cell Renal Cell Carcinoma (ccRCC)	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING
Vitamin D Dose-Response Study to Establish Dietary Requirements in Infants	PHASE2	COMPLETED
Evaluation of Tumour Growth and Oncological Treatment in Patients With CRLM Using Zebra Fish Embryo Model	PHASE1/PHASE2	UNKNOWN
EF5 Compared With Other Methods of Detecting Oxygen Levels in Tumor Cells of Patients With Head and Neck Cancer	PHASE2	COMPLETED
A Study Comparing Amorphous Calcium Carbonate (ACC) Versus Crystalline Calcium CCS) in Hypoparathyroidism Patients	PHASE1/PHASE2	COMPLETED
Phase I Trial of CArbonic Anhydrase Inhibition in Combination With Radiochemotherapy or Radioimmunotherapy in Small Cell Lung Carcinoma	PHASE1	RECRUITING
Dosimetry, Safety, and Efficacy Study of [177Lu]Lu-XT771 in Patients With Recurrent Glioblastoma	EARLY_PHASE1	RECRUITING
The Etiology and Progression of Brain Tumors	nan	COMPLETED
68Ga-C1 PET/ CT Imaging in Clear Cell Renal Cell Carcinoma	nan	RECRUITING
Incidence of Renal Tubular Acidosis in Nephrology Unit in Assiut University Childern Hospital	nan	UNKNOWN
Studying Tumor Tissue Samples From Patients Who Have Undergone Surgery for Localized Kidney Cancer	nan	WITHDRAWN
Study on the Diagnostic Value of Novel PET Molecular Imaging for Renal Cell Carcinoma	nan	RECRUITING
Role of Geminin and Mcm-2 in Prognosis of Renal Cell Carcinoma	nan	UNKNOWN
Multicenter Study of 18F-Labeled NY104 for PET/CT Imaging in Renal Cell Carcinoma	nan	RECRUITING
Radiomics: a Study of Outcome in Lung Cancer	nan	COMPLETED
Calciotropic Effects After HCG Stimulation Test	nan	COMPLETED
A Longitudinal Study to Analyse the Correlation Between CAI and Bilirubin	nan	UNKNOWN
Selecting Hypoxic Tumours for Treatment Modification	nan	RECRUITING
Exploring the Role of Serum Methylmalonic Acid (MMA) in Breast Cancer	nan	COMPLETED
PET With [18F]HX4 in Head and Neck Cancer	nan	COMPLETED
89Zr-DFO-girentuximab Expanded Access Program (EAP)	nan	NO_LONGER_AVAILABLE
The Role of HE4 in the Follow-up of Advanced Ovarian, Fallopian Tube and Primary Peritoneal Cancer	nan	UNKNOWN
Clinical Assessment of Low Calcium In traUMa (CALCIUM)	nan	ACTIVE_NOT_RECRUITING
Assessing Bone Calcium Content in Children With Kidney Disease Treated With Two Different Medicines	nan	UNKNOWN
Molecular and Immunohistochemical Profiling of Tumors in Patients With Parathyroid Tumors	nan	RECRUITING
Calcitonin in Needle Wash Using Electrochemiluminescence Method For Diagnosis Of Medullary Thyroid Carcinoma.	nan	COMPLETED
Liquid Biopsy for ctDNA in Peritoneal Lavage and Blood in Pancreatic Cancer	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a CA4 binder may also engage these)

Protein	Name	Similarity
Q95323	—	1.000	Q95323 →
P48284	—	0.992	P48284 →
Q64444	—	0.992	Q64444 →
P48283	—	0.991	P48283 →
Q99N23	—	0.982	Q99N23 →
Q8CI85	—	0.981	Q8CI85 →
Q9MZ30	—	0.978	Q9MZ30 →
CA12	Carbonic anhydrase 12	0.975	landscape →
Q865C0	—	0.970	Q865C0 →
O70354	—	0.969	O70354 →
Q95203	—	0.969	Q95203 →
Q8VHB5	—	0.968	Q8VHB5 →
Q5R665	—	0.968	Q5R665 →
Q866X7	—	0.968	Q866X7 →
CA11	Carbonic anhydrase-related protein 11	0.967	landscape →
CA6	Carbonic anhydrase 6	0.965	landscape →
P08060	—	0.962	P08060 →
Q10462	—	0.962	Q10462 →
Q866X6	—	0.962	Q866X6 →
P28651	—	0.961	P28651 →
Q9CXI3	—	0.960	Q9CXI3 →
DBH	Dopamine beta-hydroxylase	0.960	landscape →
Q6UVY6	—	0.958	Q6UVY6 →
P18915	—	0.958	P18915 →
P15101	—	0.957	P15101 →
P79263	—	0.956	P79263 →
Q9DA79	—	0.956	Q9DA79 →
Q68CI2	—	0.956	Q68CI2 →
Q8BNJ2	—	0.956	Q8BNJ2 →
Q64237	—	0.955	Q64237 →